This website uses cookies to ensure you have the best user experience. By continuing to use this website, you consent to our use of cookies. For more information, read our privacy policy.
BC200-Driven Translational Regulation as a Therapeutic Target and Biomarker in Tubo-Ovarian High-Grade Serous Carcinoma
Electrochemical Quantification of Chemotherapy Resistance
Delving deeper into chaos of ovarian cancer genomes—from telomere-to-telomere
In vivo modelling of chromosome instability in tubo-ovarian high grade serous carcinoma
The Manitoba Ovarian Cancer Biobank Program (MOBP)
Testing the in vitro mechanism and in vivo efficacy of an experimental drug to kill epithelial ovarian cancer
Investigating how a novel glycolipid drug kills chemotherapy-resistant ovarian cancer
Understanding how glycosylated antitumour ether lipids (GAELs) kill chemotherapy-resistant cancer cells
Exploring and exploiting aberrant RBX1 expression in high-grade serous ovarian cancer